Full Length Research Paper
References
|
Ajdary S, Alimohammadian MH, Eslami MB, Kemp K, Kharazmi A (2000). Comparison of the immune profile of nonhealing cutaneous Leishmaniasis patients with those with active lesions and those who have recovered from infection. Infect. Immun. 68(4):1760-1764. Crossref |
||||
|
Alexander J, Bryson K (2005). T helper (h)1/Th2 and leishmania: paradox rather than paradigm. Immunol. Lett. 99(1):17-23. Crossref |
||||
| Assafa D, Kibru E, Nagesh S, Gebreselassie S, Deribe F, Ali J (2006). Medical Parasitology. Available: http://www.cartercenter.org/resources/pdfs/health/ephti/library/lecture_notes/health_science_students/MedicalParasitology.pdf [cited 2012 April]. | ||||
|
Awasthi A, Mathur RK, Saha B (2004). Immune response to Leishmania infection. Indian J. Med. Res. 119:238-258. PMid:15243162 |
||||
|
Banuls A, Hide M, Prugnolle F (2007). Leishmania and the Leishmaniases: A parasite genetic update and advances in taxonomy, epidemiology and pathogenicity in humans. Adv. Parasitol. 64:1-109. Crossref |
||||
|
Bhattacharyya S, Dey R, Majumder N, Bhattacharjee S, Majumdar S (2008). A novel approach to regulate experimental visceral leishmaniasis in murine macrophages using CCR5 siRNA. Scand. J. Immunol. 67:345-53. Crossref |
||||
|
Bradley DJ, Kirkley J (1977). Regulation of Leishmania popuslations within the host. The variable course of Leishmania donovani infections in mice. Clin. Exp. Immunol. 30:119-29. Pubmed |
||||
|
Chappuis F, Sundar S, Hailu A, Ghalib H, Rijal S, Peeling RW, Alvar J, Boelaert M (2007). Visceral Leishmaniasis: What are the needs for diagnosis, treatment and control? Nat. Rev. Microbiol. 5:873â€82. Crossref |
||||
|
Croft SL, Coombs GH (2003). Leishmaniasis-current chemotherapy and recent advances in the search for novel drugs. Trends Parasitol. 19(11):502-8. Crossref |
||||
|
Croft SL, Sundar S, Fairlamb AH (2006). Drug Resistance in Leishmaniasis. Clin. Microbiol. Rev. 19(1):111-126. Crossref |
||||
|
Croft SL, Yardley V (2002). Chemotherapy of Leishmaniasis. Curr. Pharm. Des. 8:319-342. Crossref |
||||
|
Gregory DJ, Godbout M, Contreras I, Forget G, Olivier M (2008). A novel form of NF-kB is induced by Leishmania infection: Involvement in macrophage gene expression. Eur. J. Immunol. 38:1071-1081. Crossref |
||||
|
Gregory DJ, Sladek R, Olivier M, Matlashewski G (2008). Comparison of the effects of Leishmania major or Leishmania donovani infection on macrophage gene expression. Infect. Immun. 76:1186-1192. Crossref |
||||
| Grimaldi G Jr., Tesh RB (2012). Leishmaniasis of the New World: Current concepts and implications for future research. Clin. Microbiol. Rev. 6:230-250. | ||||
|
Grimm F, Brun R, Jenni L (2011). Promastigotes infectivity in Leishmania infantum. Parasitol. Res. 77:185-191. Crossref |
||||
|
Guizani-Tabbane L, Ben-Aissa L, Belghith M, Sassi A, Dellagi K (2004). Leishmania major amastigotes induce p50/c-Rel, NF-κβ transcription factor in human macrophages: Involvement in cytokine synthesis. Infect. Immun. 72(5):2582-2589. Crossref |
||||
|
Hotez PJ, Kamath A (2009). Neglected tropical diseases in Sub-Saharan Africa: Review of their prevalence, distribution, and disease burden. PLoS Negl. Trop. Dis. 3(8):1-10. Crossref |
||||
|
Karplus TM, Jeronimo SM, Chang H, Helms KB, Burns TL, Murray JC, Mitchell AA, Pugh EW, Braz EW, Bezzerra FL, Wilson ME (2002). Association between the Tumor Necrosis Factor Locus and the Clinical Outcome of Leishmania chagasi Infection. Infect. Immun. 70:6919-6925. Crossref |
||||
|
Kemp K, Kemp M, Kharazmi A, Ismail A, Kurtzhals JA, Hviid L, Theander TG (1999). Leishmania-specific T cells expressing interferon-gamma (IFN-γ) and IL-10 upon activation are expanded in individuals cured of visceral leishmaniasis. Clin. Exp. Immunol. 116(3):500-4. Crossref |
||||
|
Kopp E, Ghosh S (1994). Inhibition of NF-JCB by sodium salicylate and aspirin. Science 263:956-9. Crossref |
||||
|
Lapara JN, Kelly BL (2010). Suppression of LPS-induced inflammatory responses in macrophages infected with Leishmania. J. Inflamm. 7:8 Crossref |
||||
| Mansueto P, Vitale G, Seidita A, Guarneri FP, Pepe I, Rinollo C, Rosa SD, Rini G, Cillari E, Fede GD (2011). Advances in leishmaniasis immunopathogenesis. Acta Med. Mediterranea 27:7-16. | ||||
|
Marion MC, Tzeng J, Emge TJ, Ho CT, Fong D (1993). Structure-Function Analysis of Antimicrotubule Dinitroanilines against Promastigotes of the Parasitic Protozoan Leishmania mexicana. Antimicrob. Agents Chemother. 37(9):1909-13. Crossref |
||||
|
Melby PC (2002). Vaccination against cutaneous leishmaniasis: Current status. Clin. Dermatol. 3(8):557-70. Crossref |
||||
|
Mishra J, Saxena A, Singh S (2007). Chemotherapy of leishmaniasis: Past, present and future. Curr. Med. Chem. J. 14: 1153-69. Crossref |
||||
|
Mohamed HS, Ibrahim ME, Miller EN, Peacock CS, Khalil EAG, Cordell HJ, Howson JMM, El Hassan AM, Bereir REH, Blackwell JM (2003). Genetic susceptibility to visceral leishmaniasis in The Sudan: linkage and association with IL4 and IFNGR1. Genes Immun. 4(5):351-355. Crossref |
||||
|
Nolan TJ, Farrel JP (1987). Experimental infection of the multimammate rat (Mastomys natalensis) with L. donovani and L. major. Am. J. Trop. Med. Hyg. 36(2):264-269. Pubmed |
||||
|
Pearson RD, Sousa AQ (2009). Clinical spectrum of Leishmaniasis. Clin. Infect. Dis. 22:1-13. Crossref |
||||
|
Phillips SM (1993). Mechanisms of immunopathology in parasitic infections. In: Warren KS. Immunology and Molecular Biology of Parasitic Infections. Blackwell Scientific Publication, Boston, Oxford, London, Edinburgh, Melbourne, Paris, Berlin, Vienna. pp. 52-86. Pubmed |
||||
|
Reithinger R, Dujardin J, Louzir H, Pirmez C, Alexander B, Brooker S (2007). Cutaneous leishmaniasis: Review. Lancet Infect. Dis. 7:581-96. Crossref |
||||
| Rey JR (2012). Leishmaniasis. University of Florida, IFSA extension ENY-738. Available at: https://edis.ifas.ufl.edu/in705. | ||||
| Roberts MTM (2006). Current understandings on the immunology of leishmaniasis and recent developments in prevention and treatment. Brit. Med. Bull. 75:108-115. View | ||||
|
Santos DO, Coutinho CER, Madeira MF, Bottino CG, Vieira RT, Nascimento SB, Bernardino A, Bourguignon SC, Corte-Real S, Pinho RT, Rodrigues CR, Castro HC (2008). Leishmaniasis treatment—a challenge that remains: a review. Parasitol. Res. 103:1-10. Crossref |
||||
|
Teixeira MJ, Teixeira CR, Andrade BB, Barral-Netto M, Barral A (2006). Chemokines in host–parasite interactions in leishmaniasis. Trends Parasitol. 22(1):1471-4922. Crossref |
||||
| Thakur CP, Narayan S, Ranjan A (2004). Epidemiological, clinical and pharmacological study of antimony resistant visceral leishmaniasis in Bihar, India. Ind. J. Med. 120:166-172. | ||||
|
World Health Organization (2007). Sixtieth world health assembly on Control of Leishmaniasis, GENEVA, 14–23 May 2007. |
||||
|
Yamey G, Torreele E (2000). The world's most neglected diseases. BMJ 325:176-177. Crossref |
||||
Copyright © 2024 Author(s) retain the copyright of this article.
This article is published under the terms of the Creative Commons Attribution License 4.0
